231 results
POS AM
SPRC
SciSparc Ltd
2 May 24
Prospectus update (post-effective amendment)
5:17pm
in securities litigation or shareholder derivative litigation in connection with the Merger, and this could divert the attention of SciSparc and AutoMax … litigation or shareholder derivative litigation frequently follows the announcement of certain significant business transactions, such as the sale
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
, in connection with the aforementioned litigation, the shares of Evero Health Ltd. held by Capital Point are dormant and were forfeited by Evero
425
SPRC
SciSparc Ltd
12 Apr 24
Business combination disclosure
9:23am
the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the structure … Financial Statements
Shareholder Litigation
Certain Adjustments
CONDITIONS PRECEDENT TO OBLIGATIONS OF EACH PARTY
No Restraints
Shareholder Approval
6-K
EX-99.2
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
.
(d) Absence of Litigation. There is no Legal Proceeding pending or, to the knowledge of such Shareholder, threatened by, against, involving … applicable to the Parent or by which any of the Parent’s assets or properties is bound.
(c) Absence of Litigation. There is no Legal Proceeding pending
6-K
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements
6-K
EX-99.3
7psq am9msd
11 Apr 24
Agreement and Plan of Merger
4:05pm
6-K
EX-99.1
gqig6q89uc4sx3c14aq6
11 Apr 24
Agreement and Plan of Merger
4:05pm
S-8
eur 4n4owoqmnz
1 Apr 24
Registration of securities for employees
5:11pm
6-K
EX-99.1
i6nf14maz0cvh ozgdg
27 Mar 24
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
9:18am
6-K
EX-99.1
a8xm gkfx1qyy
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
6-K
w1sgyd4wz6 3la62m6y
13 Mar 24
Report of Foreign Private Issuer
9:06am
6-K
EX-99.1
ozsnxm8l
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
6-K
EX-99.3
2hnl7ju
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
6-K
EX-99.1
lyim4vpzobe6e1
29 Feb 24
Report of Foreign Private Issuer
9:07am
F-1
9ift4xvz1jpu31y11b1
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
EX-99.1
amszz64
27 Feb 24
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
8:35am
6-K
EX-99.1
itpsig
20 Feb 24
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
4:27pm
6-K
EX-99.1
4rkyiau7wsuhi zydtd
29 Jan 24
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
4:00pm
6-K
EX-10.1
ywu6p91
25 Jan 24
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
9:05am